A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Clinical trial NCT01862640 · COMPLETED

Trial details

NCT number: NCT01862640
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Agitation Associated With Alzheimer's Disease Alzheimer's Type Mental Disorder Nervous System Diseases

Start date: 2013-07-11
Primary completion: 2017-03-15
Enrollment: 433

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.